Berobenatide and retatrutide are both investigational injectable peptides for obesity, and both are in Phase 3 trials. Berobenatide, Pfizer's PF-08653944, activates a single receptor, the glucagon-like peptide-1 (GLP-1) receptor that semaglutide also targets. Retatrutide, Eli Lilly's LY3437943, activates three. Berobenatide's design centers on how long it lasts in the body, and retatrutide's on how many receptors it reaches.
Neither is approved by the U.S. Food and Drug Administration (FDA). Retatrutide has published Phase 3 results, while berobenatide's results so far come from Phase 2 trials. On November 11, 2026, Pfizer and Blackstone Life Sciences announced that funds managed by Blackstone will pay up to $1.5 billion of berobenatide's development costs through 2028.
Where berobenatide came from
Berobenatide began at Metsera, a company founded in 2022 by Population Health Partners and ARCH Venture Partners, under the code MET-097 and later MET-097i. Pfizer completed its acquisition of Metsera on November 13, 2025, and gave the compound the code PF-08653944, shortened in its announcements to PF'3944.
The name berobenatide is a proposed International Nonproprietary Name (INN), published by the World Health Organization (WHO) in 2025 in a list that classes it as a GLP-1 receptor agonist. Pfizer was using the name by June 2026.
How the two molecules differ
FDA's substance registry records berobenatide as a 41-amino-acid peptide. Its sequence starts from exendin-4, a peptide from the Gila monster lizard that is also the basis of exenatide (Byetta), which FDA approved in 2005. WHO's listing describes ten substitutions to the exendin-4 sequence and two added lysines, the last of which carries a 20-carbon fatty diacid.
Metsera attributes berobenatide's slow clearance to its HALO platform, a peptide stabilization and lipidation technology designed to let a peptide bind albumin, the most abundant protein in blood plasma, and so give it a half-life approaching albumin's own. In Metsera's Phase 1 trial, berobenatide's half-life was 380 hours, about 16 days.
Pfizer and Metsera call berobenatide a "fully biased" GLP-1 receptor agonist. A Metsera poster at the American Diabetes Association's 2025 meeting described it as G protein-biased, meaning it favors one of the signaling routes the receptor can trigger over the others.
Retatrutide is a 39-amino-acid peptide that also carries a 20-carbon fatty diacid. It activates the GLP-1 receptor, the receptor for glucose-dependent insulinotropic polypeptide (GIP) and the glucagon receptor, and mazdutide vs retatrutide vs survodutide covers what each of those receptors adds.
One amino acid on each side of FDA's line
Chain length matters for how FDA regulates a peptide. FDA's 2020 rule defines a protein, which is licensed as a biological product, as an alpha amino acid polymer of more than 40 amino acids. Retatrutide's 39-amino-acid backbone is at the center of Lilly's dispute with FDA over that definition, covered in our post on FDA's October 2026 retatrutide decision.
Berobenatide's chain is 41 amino acids long by FDA's own registry. Metsera said in September 2025 that it was developing the compound through FDA's biologic pathway, with the intent to seek approval under a Biologics License Application (BLA).
Trial results so far
Berobenatide's figures come from ClinicalTrials.gov and from Pfizer and Metsera announcements:
- VESPER-1 randomized 239 adults with obesity or overweight and without type 2 diabetes for 28 weeks. Across four doses, placebo-adjusted weight loss ranged from 8.1% to 14.1% at week 28, counting only weights measured while participants stayed on treatment.
- VESPER-3 enrolled 268 adults and tested four regimens, two of which Pfizer plans to carry into Phase 3. Placebo-adjusted weight loss at week 28 reached 12.3% on the same on-treatment basis.
- VESPER-2 enrolled 133 adults with obesity or overweight and type 2 diabetes. At 28 weeks, HbA1c (a measure of average blood sugar) fell 2.2 percentage points with one dose, against 0.2 with placebo, on the same basis.
For the two VESPER-3 regimens planned for Phase 3, Pfizer also reported placebo-adjusted weight loss counting all available weights whether or not participants stayed on treatment: 8.4% and 10.5%. In VESPER-1, two of the 239 participants stopped treatment because of adverse events, Metsera reported.
Retatrutide's Phase 3 results are published. TRIUMPH-1 (New England Journal of Medicine, 2026) randomized 2,339 adults with obesity or overweight and without diabetes for 80 weeks. Weight fell 25.0% in the highest-dose group, against 3.9% with placebo, counting participants whether or not they stayed on treatment. Lilly's announcement led with 28.3% against 2.2%, an estimate of the effect had every participant stayed on treatment.
The trials differ in phase, length and population, and berobenatide's figures are differences from placebo while TRIUMPH-1's are reported for each group. They cannot rank the two compounds, and retatrutide vs tirzepatide vs semaglutide explains why separate trials do not settle that.
The Phase 3 programs
As of November 12, 2026, ClinicalTrials.gov lists 13 Pfizer-sponsored Phase 3 trials of berobenatide. The largest, VESPER-4, enrolled 3,578 adults with obesity or overweight and without type 2 diabetes, with its primary endpoint at 64 weeks. The others cover:
- A second obesity trial (VESPER-6) and adults with obesity or overweight and type 2 diabetes (VESPER-5).
- Obstructive sleep apnea, in adults who use positive airway pressure therapy and in adults who do not.
- Knee osteoarthritis, in two trials.
- Weight maintenance in adults switching from semaglutide or tirzepatide.
- Adults in Japan (two trials) and in China (two trials).
- Stress urinary incontinence in women, in a trial not yet recruiting.
Retatrutide's Phase 3 program, TRIUMPH, covers several of the same conditions, including knee osteoarthritis and obstructive sleep apnea. Lilly said in September 2026 that it plans to submit retatrutide to FDA in the first quarter of 2027.
Pfizer is also testing berobenatide with an amylin analog, PF-08653945 (MET-233i), from the same drug class as cagrilintide. The Phase 2b trial SOLIS-1, which enrolled 940 participants, tests that analog alone and combined with berobenatide.
Under the Blackstone agreement, Blackstone is eligible for milestone payments tied to U.S. approval and sales, and it takes no rights or ownership in berobenatide.
Approval status and research listings
Drugs@FDA, the agency's database of approved products, returns no record for berobenatide, and Pfizer described it as investigational on November 11, 2026. PeptideScouter indexes no berobenatide listings.
As of November 12, 2026, 43 of the 46 vendors in our index have retatrutide in stock. Its median price for a single 10mg vial is $6.80 per mg across 41 vendors, one price per vendor. Research vendors often sell retatrutide under product codes such as GLP-3, and what GLP-3 means explains them. Definitions are on the methodology page.
Sources
- WHO Drug Information, Proposed INN List 133 (2025): the name berobenatide, its class and its chemical description.
- FDA Global Substance Registration System, berobenatide and retatrutide: chain lengths and fatty-acid modifications.
- Metsera, Phase 1 results, September 24, 2024: the 380-hour half-life and Metsera's founders.
- Metsera, ADA 2025 presentations, June 5, 2025: the G protein-biased poster.
- Metsera, VESPER-1 results, September 29, 2025: the HALO platform, discontinuations and the planned BLA pathway.
- Pfizer, completion of the Metsera acquisition, November 13, 2025.
- Pfizer, VESPER-3 results, February 3, 2026: the PF-08653944 code and VESPER-3 figures by analysis.
- Pfizer, Phase 2b results at ADA, June 6, 2026: the name berobenatide, VESPER-2 and SOLIS-1.
- Pfizer and Blackstone Life Sciences, co-funding agreement, November 11, 2026.
- ClinicalTrials.gov, VESPER-1, NCT06712836 (posted results), VESPER-2, NCT06897202, VESPER-3, NCT06973720, VESPER-4, NCT07311850 and SOLIS-1, NCT07575932.
- ClinicalTrials.gov, berobenatide trial records: the Phase 3 trials, their sponsors and populations.
- 21 C.F.R. 600.3: FDA's definition of a protein at paragraph (h)(6).
- Drugs@FDA, Byetta (exenatide), NDA 021773: the 2005 approval.
- Jastreboff and colleagues, New England Journal of Medicine, 2026: TRIUMPH-1 published results.
- Lilly, TRIUMPH-1 topline results, May 21, 2026: the 28.3% figure and its basis.
- Lilly, TRIUMPH-2 detailed results, September 29, 2026: the planned submission to FDA.
- Drugs@FDA: FDA's database of approved drug products.
Prices are as of November 12, 2026, computed from PeptideScouter's own price index. Sources checked November 12, 2026.